Cresco Labs Inc. (CRLBF)
(Delayed Data from OTC)
$2.18 USD
+0.02 (1.00%)
Updated May 3, 2024 03:59 PM ET
2-Buy of 5 2
B Value B Growth D Momentum A VGM
Brokerage Reports
0 items in cart
Cresco Labs Inc. [CRLBF]
Reports for Purchase
Showing records 61 - 80 ( 121 total )
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
4Q22 Rationalization Focus on Optimization, Lower to Neutral & $1.75 PT
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Q422 Underwhelms on Margins/EBITDA and Outlook Soft. Move to Hold Rating
Provider: Echelon Welath Partners
Analyst: SEMPLE A
Company: Cresco Labs Inc.
Industry: Medical - Products
Tightening Capital Markets Conditions Poses Both Risks and Opportunities for Cannabis Companies
Provider: Echelon Welath Partners
Analyst: SEMPLE A
Company: Cresco Labs Inc.
Industry: Medical - Products
Cannabis Industry: Monthly Performance and Valuations February ''23
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Announces Timeline Extension to Close Cresco/Columbia Acquisition
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly ReHash: 280E Removal Would Bring More Than Just Financial Leverage
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly Rehash: U.S. Interstate Commerce the Long Game
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly ReHash: Scoring the MSOs with Cash Flow, Debt and Valuations
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly ReHash: Pricing is Key to Improving Industry Fundamentals
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Cannabis Industry Update: 2022 Performance and Valuations
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly ReHash: Putting 2022 Performance & Valuations Behind Us
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
Initiating Coverage of U.S. Cannabis: Setting Stage for Greener Pastures
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Cresco Labs Inc.
Industry: Medical - Products
Initiating Coverage at Outperform: Room to Go for Cresco
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly ReHash: 3Q Cannabis Earnings Recap, Inflationary Pressures Impacting NT
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S